All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak with Daniel Chen, University College Hospitals, London, UK. We asked, How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
Chen begins by highlighting the increased recognition of cardiovascular complications and toxicity in CAR T-cell treatment and their manifestations. He discusses some retrospective analyses that tried to identify patients most at risk of developing these complications. Finally he outlines the risk factors for cardiovascular toxicities such as high disease burden and cytokine release syndrome.
Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells
The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in China. Jianxiang Wang presented this topic at the 2nd...
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two anti-CD19 chimeric antigen receptor (CAR) T-cell...
Subscribe to get the best content related to ALL delivered to your inbox